Linnaeus Therapeutics, Inc.
Clinical trials sponsored by Linnaeus Therapeutics, Inc., explained in plain language.
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called LNS8801, given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink t…
Phase: PHASE1, PHASE2 • Sponsor: Linnaeus Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
New hope for tough melanoma: drug combo trial launches
Disease control Recruiting nowThis study tests a new oral drug, LNS8801, alone or with pembrolizumab, in people with advanced melanoma that has stopped responding to standard treatments. About 135 participants will be randomly assigned to one of three groups: LNS8801 alone, LNS8801 plus pembrolizumab, or stan…
Phase: PHASE2, PHASE3 • Sponsor: Linnaeus Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC